Dr. Chi on Tazemetostat in Pediatric Patients With INI1-Negative Tumors

Susan N. Chi, MD
Published: Friday, Nov 16, 2018



Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the EZH2 inhibitor tazemetostat in pediatric patients with INI1-negative tumors.

In a phase I study of pediatric patients with INI1-negative rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma tumors, tazemetostat showed promising antitumor activity. Chi reports that the drug was very well-tolerated, and the side effects seen were nausea, vomiting, and a small amount of bone marrow suppression. Tolerability is important for these children, as they have previously undergone intensive regimens of chemotherapy and radiation, Chi adds.

There was 1 case of a secondary malignancy. Chi says that she and her fellow investigators are currently evaluating this case. They are working on determining the relationship with the inhibitor and how it can be prevented in the future. Still, these findings have led to a phase II trial, where tazemetostat will be given at a recommended dose of 1200 mg/m2 divided twice daily.  
SELECTED
LANGUAGE


Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the EZH2 inhibitor tazemetostat in pediatric patients with INI1-negative tumors.

In a phase I study of pediatric patients with INI1-negative rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma tumors, tazemetostat showed promising antitumor activity. Chi reports that the drug was very well-tolerated, and the side effects seen were nausea, vomiting, and a small amount of bone marrow suppression. Tolerability is important for these children, as they have previously undergone intensive regimens of chemotherapy and radiation, Chi adds.

There was 1 case of a secondary malignancy. Chi says that she and her fellow investigators are currently evaluating this case. They are working on determining the relationship with the inhibitor and how it can be prevented in the future. Still, these findings have led to a phase II trial, where tazemetostat will be given at a recommended dose of 1200 mg/m2 divided twice daily.  



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x